Last updated on November 2018

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)


Brief description of study

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Clinical Study Identifier: NCT02568267

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GO40782 ...

Wheaton Franciscan Cancer Care-All Saints
Franklin, WI United States
  Connect »